Edgen Stock·Dec 01 2025, 10:00返回
返回
再生元制药股价因Eylea HD药物获批和Dupixent强劲销售数据而上涨
Edgen Stock·Dec 01 2025, 10:00
[1] FDA批准Eylea HD用于视网膜静脉阻塞后黄斑水肿 (https://www.healio.com/news/ophthalmology/202 ...)[2] FDA批准阿柏西普注射液用于黄斑水肿... (https://www.drugtopics.com/view/fda-approves- ...)[3] 再生元的EYLEA HD 8毫克注射剂获得FDA批准用于... (https://www.ophthalmologytimes.com/view/regen ...)